LUNG: Revenue growth returned as adjusted EBITDA loss nearly halved and FY guidance held
Pulmonx Corporation reported Q3 2026 revenue growth in U.S. and international markets, with adjusted EBITDA loss decreasing by nearly 60%. The company maintained FY 2026 revenue guidance of $90M–$92M, citing cost discipline and sales-team productivity.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance reaffirmation could trigger a short‑term rally, especially in after‑hours trading.
Market read
First‑time Q3 earnings disclosure for LUNG provides fresh data that may move the stock.
What to watch
Potential competitive pressure and reimbursement uncertainties not addressed in the release.
Background
Pulmonx Corp (LUNG) reported Q3 2026 earnings, showing a return to YoY revenue growth and a 60% reduction in adjusted EBITDA loss, while reaffirming FY revenue guidance.
Ticker impact
Q3 2026 results show revenue growth and EBITDA loss narrowed 60%, with FY guidance reaffirmed at $90M‑$92M.
likely upside as investors price in stronger top‑line and narrowed loss.
First‑time disclosure of Q3 numbers and guidance for a micro‑cap; market typically reacts positively to revenue growth and EBITDA improvement.
Market effects
Signals improving demand in the pulmonary medical devices sector.
May boost sentiment for US biotech micro‑caps.
Limited to niche medical device investors.
Counterpoint
Revenue growth may be unsustainable; guidance still modest, could limit upside.
Key entities
- companyPulmonx Corporation
US‑listed medical device maker focused on pulmonary therapies.
